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Introduction
The extensive use of classical antibiotics has led to the emergence of increasing resistance among bacteria (10) . In this perspective, cationic antimicrobial peptides (AMPs) are interesting since they provide a rapid and broad-spectrum response towards both Gramnegative and Gram-positive bacteria, as well as fungi. Although AMPs may influence bacteria in a multitude of ways (3), bacterial wall rupture seems to play a key role in the bactericidal action of most AMPs. During recent years it has become increasingly evident that many AMPs are multifunctional, also mediating various immunomodulatory roles and angiogenesis (7, 12, 14, 26, 45, 48) , thus motivating the recent and broader definition host defense peptides (HDP) for these members of the innate immune system. The family of HDPs has recently been shown to encompass a diverse family of peptides, including proinflammatory and chemotactic chemokines (4), neuropeptides (3), peptide hormones (19, 27) , growth factors (22) , the anaphylatoxin peptide C3a (30, 34) , and kininogen-derived peptides (11, 29, 39) . We have previously shown that C-terminal peptides of thrombin constitute a novel class of HDPs, released upon proteolysis of thrombin in vitro, and detected in human wounds in vivo. These peptides exert antimicrobial effects against Gram-positive and Gram-negative bacteria, mediated by membrane lysis, as well as immunomodulatory functions, by inhibiting macrophage responses to bacterial lipopolysaccharide (31) . In mice, they are protective against P. aeruginosa sepsis, as well as lipopolysaccharide-induced shock.
Moreover, the thrombin-derived C-terminal peptides exhibit helical structures upon binding to lipopolysaccharide, and permeabilize liposomes, features typical of "classical" helical AMPs. These findings provide a novel link between the coagulation system and host-defense peptides, two fundamental biological systems activated in response to injury and microbial invasion. Although peptides were identified with these advantageous properties, however, the previous work provided no insight whether these peptides, or shorter sequences in these, are responsible for the effects observed. In the present study, we therefore set out to investigate minimal determinants, as well as structural features, governing the antimicrobial and immunomodulating activity of this peptide region.
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MATERIALS AND METHODS
Peptides. Peptides were from Sigma-Genosys, generated by a peptide synthesis platform (PEPscreen®, Custom Peptide Libraries, Sigma Genosys). Prior to biological testing the PEPscreen peptides were diluted in dH 2 0 (5 mM stock), and stored at -20ºC. This stock solution was used for the subsequent experiments. Selected peptides were synthesized by Biopeptide, San Diego, US. The purity (>95%) and molecular weight of these peptides was confirmed by both suppliers by mass spectral analysis (MALDI.TOF Voyager). LL-37 was from Innovagen AB, Lund, Sweden (purity >95%).
Microorganisms. Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853
Staphylococcus aureus ATCC 29213, and Candida albicans ATCC 90028 were obtained from the Department of Clinical Bacteriology at Lund University Hospital. Additional S.
aureus clinical isolates were obtained from patients with skin infections.
Radial diffusion assay. Essentially as described earlier (20, 30) bacteria were grown to midlogarithmic phase in 10 ml of full-strength (3% w/v) trypticase soy broth (TSB) (BectonDickinson, Cockeysville, MD). Candida was grown for 16 h at 28ºC in 10 ml TSB medium to obtain yeast form organisms. The microorganisms were then washed once with 10 mM After agarose solidification, 4 mm-diameter wells were punched and 6 l of test sample was added to each well. Plates were incubated at 37ºC for 3 hours to allow diffusion of the peptides. The underlay gel was then covered with 15 ml of molten overlay (6% TSB and 1% Low-EEO agarose in distilled H 2 O). Antimicrobial activity of a peptide is visualized as a zone of clearing around each well after 18-24 hours of incubation at 37°C.
Viable-count analysis. E. coli ATCC 25922 bacteria were grown to mid-logarithmic phase in Todd-Hewitt (TH) medium (Becton and Dickinson, Maryland, USA). The microorganisms were then washed and diluted in 10 mM Tris, pH 7.4 containing 5 mM glucose. Following this, bacteria (50 µl; 2 x 10 6 cfu/ml) were incubated, at 37°C for 2 hours, with the peptides 4 GKY25, GKY20, YTH20, or FYT20 (at 0.03, 0.06, 0.3, 0.6, 3, 6, 30, 60 µM) in 10 mM Tris, pH 7.4, 0.15 M NaCl, with or without 20% human citrate-plasma. In the experiments using 50% whole blood, S. aureus ATCC 29213 and P. aeruginosa ATCC 27853 bacteria (50 µl; 2 x 10 8 cfu/ml) were incubated at 37°C for 1 hour in the presence of peptide at 60 (for P. aeruginosa) and 120 µM (P. aeruginosa and S. aureus). To quantify the bactericidal activity, serial dilutions of the incubation mixtures were plated on TH agar, followed by incubation at 37°C overnight and the number of cfu was determined. One hundred percent survival was defined as total survival of bacteria in the same buffer and under the same condition in the absence of peptide. Significance was determined using the statistical software SigmaStat (SPSS Inc., Chicago, IL, USA).
Hemolysis assay.
For experiments in 50% blood, citrate-blood was diluted (1:1) with PBS.
The cells were then incubated with end-over-end rotation for 1 h at 37°C in the presence of peptides (60 or 120 µM). Two per cent Triton X-100 (Sigma-Aldrich, St. Louis, USA) served as positive control. The samples were then centrifuged at 800 g for 10 min. The absorbance of hemoglobin release was measured at 540 nm and is expressed as % of TritonX-100 induced hemolysis. In the experiments with blood infected by bacteria, citrate-blood was diluted (1:1) with PBS. The cells were then incubated with end-over-end rotation for 1 h at 37°C in the presence of peptides (60 and 120 µM) and S. aureus (2 x 10 8 cfu/ml) or P. aeruginosa (2 x 10 8 cfu/ml) bacteria. For evaluation of hemolysis, samples were then processed as above. Animal infection model. P. aeruginosa 15159 bacteria were grown to logarithmic phase (OD 620~0 .5), harvested, washed in PBS, diluted in the same buffer to 2 x 10 8 cfu/ml, and kept on ice until injection. One hundred microliter of the bacterial suspension was injected i.p. into female C57/BL6 mice. Thirty minutes after the bacterial injection, 0.5 mg GKY20 or buffer alone was injected i.p. into the mice. In order to study bacterial dissemination to target organs spleen, liver and kidney were harvested, placed on ice, homogenized, and cfu determined. The P-value was determined using the Mann-Whitney U-test. Data from three independent experiments were pooled. Calculations. Relative hydrophobic moment (µHrel) was calculated using the web-based algorithm found at http://www.bbcm.univ.trieste.it/~tossi/HydroCalc/HydroMCalc.html.
Minimal inhibitory concentration assay (MIC)
.
RESULTS
Previous x-ray crystallographic studies of intact thrombin have shown that the C-terminal region (HVFRLKKWIQKVIDQFGE) adopts an α-helical conformation in the thrombin molecule (2) . As an isolated peptide, on the other hand, this region adopts a dynamic random coil conformation in aqueous solution (31) . Nevertheless, the peptide GKY25 (GKYGFYTHVFRLKKWIQKVIDQFGE) has the ability to adopt a helical conformation in specific solvent environments, such as the presence of LPS (31) . It is notable that the peptide contains a helix stabilizing N-cap motif of the C-terminal helix. Furthermore, the side chain of H8 (in GKY25) makes a hydrogen bond to the backbone amide three residues downstream 9 (R11). Of relevance for this peptide region is also the observation that a spacing of i, i + 3 or i, i + 4 between hydrophobic residues such as L, I, and W is known to stabilize helices with the latter spacing giving the strongest interaction (21) . In order to evaluate minimal antimicrobial epitopes of GKY25, as well as determine the potential hemolytic effects of these shorter fragments, peptides sequentially truncated from either the C-or N-terminus were analyzed in RDA against E. coli as well as tested for hemolysis using human erythrocytes. As shown in Figure 1 , bactericidal activities were retained for shorter fragments, as particularly noted for the C-and the simultaneously N-and C-terminally truncated peptides. In general, the presence of 0,15 M NaCl was slightly inhibitory on peptide antimicrobial activity. It is notable that the short N and C-terminally truncated 12-mer peptide, VFRLKKWIQKVI, containing the central "core", retained good bactericidal potency at high salt conditions (Fig. 1A) . In general, peptides having lengths of above 18-20 amino acids displayed hemolytic effects at the concentration tested (60 µM) (Fig. 1 A) . The antimicrobial analyses were extended to the Gram-negative P. aeruginosa, the Grampositive S. aureus, and the fungus C. albicans (Fig. 1 B) . Apart from showing the broad spectrum activity of GKY25, the results illustrate that GKY-derived peptides of shorter length (down to 8-10 amino acid residues) retain most of their activity at the low salt conditions used. Hence, taken together, the results illustrate that hemolytic and antibacterial effects partly overlap, although there is a tendency that shorter peptide fragments of [15] [16] [17] [18] [19] [20] amino acids retain good antimicrobial activity, yet relatively limited hemolysis. In order to further delineate some structural prerequisites determining activity, we synthesized 16-mer peptides based on the internal sequence THVFRLKKWIQKVIDQ (z net = +4), encompassing the critical N-and C-cap motifs, but having the cationic R and K-residues sequentially replaced by S. It is notable that among the peptides having one K replaced (z net = 3), the central K residue N-terminal of W appeared to be the most critical for antimicrobial activity, particularly against S. aureus. Introducing one more change in this peptide, again in the central part, and C-terminal of Q, almost completely abrogated the activity of the peptide (Fig. 2) . Thus, the results indicate that the two central K residues adjacent to the evolutionary conserved WI sequence are particularly important for determining the antimicrobial activity of this region of the peptide.
Given the potent anti-endotoxic effects of GKY25, we next studied the length dependence of the anti-inflammatory effect in a macrophage model. As seen in Figure 3 Next, we analyzed selected peptides corresponding to three major groups, i) peptides of 20 amino acids showing "dual" effects (exerting both antimicrobial activity in high salt and anti-inflammatory activity), ii) those only yielding antimicrobial effects in high salt (of 16 amino acids), and iii) those only showing activity in low salt buffers. MIC assays using various E. coli and S. aureus strains showed that only the 20-mer peptides, and particularly the C-terminally truncated GKYGFYTHVFRLKKWI (GKY20), and the N-and Cterminally truncated FYTHVFRLKKWIQKVIDQFG (FYT20) presented low MICs comparable to that of the parent GKY25, as well as the benchmark peptide LL-37 (Fig. 4A) .
It was also noted that the pure FYT20 peptide displayed some turbidity when dissolved at 5 mM, likely illustrating the high hydrophobicity and amphipathicity of this particular peptide region. In order to further explore the effects of these peptides in relevant physiological environments, viable count assays in 0.15 M NaCl and in presence of 20% human plasma were performed (Fig. 4B) . Whereas GKY20 showed similar antimicrobial activities in both environments, the N-and C-terminally truncated FYT20, as well as N-terminally truncated YTH20, were significantly inhibited, particularly in human plasma (Fig. 4B ). Anti-endotoxin activity was probed for the truncated variants and compared with activity of the full-length GKY25. In correspondence with the initial screening results, the 20-mer peptides showed anti-inflammatory activities at or below 10 µM, in contrast to the shorter 16-and 12-mer variants. Interestingly, GKY16 still retained some activity at 50 µM (Fig. 5A) . At 10 µM, the 20-mer peptide variants also inhibited LTA-and zymosan-induced NO-release from macrophages (Fig. 5B) .
The 20-mer peptides all showed less hemolysis than the original GKY25 peptide, as well as LL-37 (Fig. 6A) , however, it was noted that the dose of GKY25 required for permeabilization of erythrocytes significantly exceeded the MIC values (Fig. 4A) , as well as the concentration required for efficient bacterial killing in the viable count assays (Fig. 4B) .
Likewise, the 20-mer variants affected viablility to a lesser extent than GKY25 as well as LL-37, although the LDH-release was similar. In the presence of serum, on the other hand, the 20-mers displayed no detectable permeabilization with either LDH release or MTT assay 11 (Fig. 6B) . It was noted that both GKY25 and LL-37 showed some permeabilizing activity also in serum at 60 µM (Fig. 6B) . Analogously, permeabilization of human skin fibroblasts by the 20-mer peptides was largely absent at 60 µM, in contrast to the findings obtained with GKY25 as well as LL-37 (Fig. 6C) . In order to simultaneously explore hemolytic (Fig. 7A) as well as antimicrobial effects (Fig. 7B) , of importance for subsequent in vivo studies, the two peptides GKY25 and GKY20 were added to human blood infected by S. aureus or P.
aeruginosa. It was observed that the peptides, and particularly GKY20, displayed a significant selectivity, demonstrating almost complete eradication of P. aeruginosa and S. aureus, with little (~ 5% or less) accompanying hemolysis, at a peptide dose of 120 µM.
Taken together, the combination of hemolysis results and permeabilization studies on HaCat keratinocytes as well as human fibroblasts indicate that the truncated peptides, and particularly GKY20, show reduced toxicity at doses above those needed for antimicrobial as well as anti-inflammatory effects. Figure 8A shows that like GKY25, the 20-mer variants permeabilized E. coli cells, as visualized with the impermeant probe FITC. To further examine peptide-induced permeabilization of bacterial plasma membranes, P. aeruginosa and S. aureus was incubated with GKY20 at concentrations yielding complete bacterial killing (30 µM), and analyzed by electron microscopy (Fig. 9B ). Clear differences in morphology between peptide-treated bacteria and the control were demonstrated. The peptide caused local perturbations and breaks along P. aeruginosa and S. aureus plasma membranes, and intracellular material was found extracellularly. In order to obtain further structural and mechanistic information, we studied GKY25 (GKYGFYTHVFRLKKWIQKVIDQFGE), GKY20 (bold in previous sequence), as well as the epitope VFRLKKWIQKVI (VFR12, in italics), the latter retaining significant antimicrobial effects when compared with GKY20. As demonstrated in Figure 8C , the peptides showed mostly a random coil conformation in buffer. However, LPS induced a conformational change in all the three peptide variants. In contrast, as seen in the CDspectrum (Fig. 8C) , and depicted in Figure 8D , anionic liposomes significantly affected helix content only for GKY25. Despite this, GKY25 and GKY20 showed similar membrane disruptive effects on liposomes, and their activity in this context was significantly higher when compared with VFR12 (Fig. 8E) , likely reflecting a lower entropy penalty for membrane insertion for these longer peptides compared to the shorter VFR12, in analogy to effects found previously, e.g., for cardin consensus peptides (37) . Taken together, the above studies demonstrated the possibility of maintaining desired antimicrobial and anti-inflammatory effects, while reducing peptide length and attenuating peptide toxicity. The peptide GKY20, meeting prerequisites of little inhibition in plasma, reduced toxicity, as well as maintained MIC values and antiinflammatory effects, was selected in order to further investigate the potential therapeutic effectiveness in vivo. We therefore injected this peptide into mice infected intraperitoneally with P. aeruginosa.
Compared to the controls, treatment with GKY20 reduced bacterial numbers in the spleen, liver, and kidney of the animals (Fig. 9A) . In a mouse model of LPS-induced shock, GKY20 displayed a dramatic improvement on survival (Fig. 9B, left panel) . The treated animals also showed recovery of weight (Fig. 9B, right panel) . Analyses of platelet counts after 12 h showed that GKY20 significantly increased platelets, indicative of reduced consumption in this particular LPS-model (Fig. 9C) . Analyses of cytokines 20 hours after LPS injection showed significant reductions of proinflammatory IL-6, IFN-γ, TNF-α, and MCP-1, whereas an increase in anti-inflammatory IL-10 was observed (Fig. 9D) . Furthermore, a marked reduction of inflammation and vascular leakage in the lungs of the GKY20-treated animals was observed after histochemical evaluation of the lungs (Fig. 9E) . Correspondingly, while SEM analyses of the lungs from LPS-treated animals demonstrated pulmonary leakage of protein and red blood cells (Fig. 10F) , lungs of GKY20-treated animals showed marked reductions of these LPS-induced effects. The results thus demonstrate the therapeutic potential of GKY20 in these animal models of P. aeruginosa sepsis and LPS-induced shock.
DISCUSSION
Considering the increasing resistance problems against conventional antibiotics, a number of HDPs and peptidomimetics are currently undergoing clinical trials (6, 14, 16, 24) . In most cases, trials are aimed at topical indications where direct microbicidal effects are utilized.
Considering this property of AMPs, various strategies have been employed in order to optimize the therapeutic index including use of combinational library approaches (1), stereoisomers composed of D-amino acids (40) or cyclic D,L--peptides (8), QSAR and high-throughput based screening assays (9, 15, 18, 35, 44) . Furthermore, a novel approach for boosting AMPs through end-tagging with hydrophobic oligopeptide stretches have recently been demonstrated (23, 32, 33, 41) . The peptides were active ex vivo and in vivo in porcine S. aureus skin infection models, and in P. aeruginosa infected wound models (23, 13 32, 33, 41). Immunomodulatory peptides have recently gained much interest due to their capacity to selectively boost or down-regulate immune effectors during infection (17, 25, 26, 28, 43, 45) . Naturally occuring peptide epitopes may show promise in a therapeutic setting considering low immunogenecity paired with the endogenous immunomodulatory activities described here. However, as shown in the present study on the thrombin-derived GKY25, a systematic analysis of epitopes with respect to size as well as sequence is required in order to define and select peptide regions with preferred activities with respect to efficiency and therapeutic index. The necessity of this appproach is exemplified by the observation that even minor differences in selection of the active 20-mer region, yielded diffferent activities with respect to inactivation by plasma, observed MIC values, as well as anti-inflammmatory effects. It is also possible, that the GKY20 sequence could be used as a template in order to further define and possibly enhance the immunomodulatory activities of the peptide, a strategy succesfully used for other peptides (6, 28). Finally, the results demonstrate that a concerted approach, utilizing not only experiments with erythrocytes in PBS, but also including results obtained in plasma and blood are required in order to better assess potential toxic effects of a given peptide.
Considering the endotoxin neutralizing activities, the mode of action GKY20 may involve binding to and neutralization of LPS, yielding inhibition of subsequent TLRsignaling, as described for other helical peptides (38) . However, it is also possible that the peptide acts by additional mechanisms, which involve direct effects on host cells such as macrophages. In relation to this, it is notable that the 12-mer peptide VFR12, while showing binding and induction of a helical conformation in presence of LPS, was not able to block LPS effects in the macrophage model. As the latter requires a size of at least 19-20 amino acids, the results suggest that additional mechanisms, apart from direct LPS-binding, may contribute to the observed anti-endotoxin effects. Indeed, and in line with this reasoning, hydrophobically tagged peptides with high affinity for LPS (32, 33, 41) showed little antiinflammatory effects in the macrophage models used here (data not shown). The possible mechanisms underlying the function of GKY20/GKY25 remain to be investigated but may include interactions with CD14, TLRs, or intracellular receptors.
As demonstrated here, peptides derived from natural HDPs, such as exemplified by GKY20, can be interesting since they retain the main properties of the parent molecule. Considering the significant anti-inflammatory effects, but modest direct antimicrobial activity of GKY20 in vivo, the potential use of this HDP may be in situations Lungs were analyzed by scanning electron microscopy 20 h after LPS injection i.p., followed by treatment with GKY20 (500 µg) or buffer. Treatment with the peptide blocked leakage of proteins and erythrocytes (n=3 in both groups, and a representative lung section is shown).
